Kopexil

• CAT Number: M013760
• CAS Number: 74638-76-9
• PubChem Substance ID: 10197687
• Molecular Formula: C4H6N4O
• Molecular Weight: 126.12
• Purity: ≥95%
• IUPAC Name: 3-hydroxy-2-iminopyrimidin-4-amine
• InChI: InChI=1S/C4H6N4O/c5-3-1-2-7-4(6)8(3)9/h1-2,6,9H,5H2
• InChIKey: YTKGAYFHUZTLCI-UHFFFAOYSA-N
• SMILES: C1=C(N(C(=N)N=C1)O)N

Kopexil (INCI name diaminopyrimidine oxide, trade name Aminexil)(CAS: 74638-76-9) is a chemical compound similar to minoxidil. Minoxidil was originally used to treat high blood pressure; a side effect was increased body hair. Both compounds have been used for therapy of alopecia. Kopexil is not approved for use as a drug in the United States or in Europe.

Reference

[1]. Praxis (Bern 1994). 2001 Feb 15;90(7):241-8.
[Status of scalp hair and therapy of alopecia in men in Switzerland].
[Article in German]
Trüeb RM(1), de Viragh PA; Schweizerische Arbeitsgruppe fur Trichologie.
Author information: (1)Universitätsspital Zürich Gloriastrasse 31 8091 Zürich.
A community-based interview and a questionnaire of men visiting the dermatologist for treatment of hair loss were conducted in Switzerland, to characterize the significance of scalp hair and self-perception of hair loss in Swiss men, and to evaluate current treatment of hair loss. 508 men, aged 15-74 years, regardless of the degree of hair loss, were interviewed by telephone, and 308 patient questionnaires were completed by 19 dermatologists. The questions addressed by the interview were: degree of self-rated hair loss, time invested for hair care, use or reasons for rejecting hair growing agents, relevant criteria for scalp hair, self-assessment with respect to different "hair communication types". The questionnaire analysed the causes of hair loss, prior and current treatment modalities, and follow-up at the dermatologist. Respondents rated their hair loss on a 5-point, textual scale that ranged from 'no hair loss' to 'bald areas'. 43% reported hair loss to some extent. For 42% a full head of hair was very important, especially for men under 29 years, who invested more time for hair care and had not lost hair. Of men with hair loss, 26% previously applied hair growing agents. Of men consulting the dermatologist for hair loss, 90% had androgenetic alopecia. 37% were previously treated: prior treatment was in 59% minoxidil, in 4% finasteride (Propecia), in 7% Aminexil, in 7% dietary supplements, and in 6% conducted by the hair dresser. In 79% treatment was switched to Propecia: of these, 73% adhered to the follow-up consultations at the dermatologist.
PMID: 11256223

[2]. MSDS for Kopexil at Kumar Organics. Archived 2015-07-22 at the Wayback Machine March 28th 2012.

[3]. Wolfgang Raab: Haarerkrankungen in der dermatologischen Praxis, p. 82, at Google Books (German).